[go: up one dir, main page]

MX2017008187A - Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr. - Google Patents

Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.

Info

Publication number
MX2017008187A
MX2017008187A MX2017008187A MX2017008187A MX2017008187A MX 2017008187 A MX2017008187 A MX 2017008187A MX 2017008187 A MX2017008187 A MX 2017008187A MX 2017008187 A MX2017008187 A MX 2017008187A MX 2017008187 A MX2017008187 A MX 2017008187A
Authority
MX
Mexico
Prior art keywords
compositions
listeria
protein
tumor
inducing
Prior art date
Application number
MX2017008187A
Other languages
English (en)
Inventor
Wallecha Anu
Petit Robert
KHLEIF Samir
Mkrtichyan Mikayel
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2017008187A publication Critical patent/MX2017008187A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se describen composiciones que comprenden el uso de composiciones que comprenden una cepa de Listeria recombinante viva atenuada que comprende una proteína de fusión de una proteína listeriolisina O (LLO) truncada, una proteína ActA truncada, o una secuencia de aminoácidos PEST fusionada a un antígeno heterólogo, que incluye un antígeno asociado a un tumor, en donde las composiciones comprenden, además, o se administran conjuntamente con un anticuerpo o un fragmento de este. Se describen, además, terapias de combinación que comprenden el uso de estas composiciones que comprenden cepas de Listeria recombinantes vivas atenuadas, junto con un anticuerpo o un fragmento de este para el uso en el tratamiento, ña protección contra, y/o la inducción de una respuesta inmunitaria contra un tumor, especialmente en donde el tratamiento, la protección contra y/o la inducción de una respuesta inmunitaria aumenta el por ciento de supervivencia en un sujeto.
MX2017008187A 2014-12-19 2015-12-18 Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr. MX2017008187A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462094472P 2014-12-19 2014-12-19
US201462094349P 2014-12-19 2014-12-19
US201562147463P 2015-04-14 2015-04-14
US201562262896P 2015-12-03 2015-12-03
PCT/US2015/066896 WO2016100929A1 (en) 2014-12-19 2015-12-18 Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies

Publications (1)

Publication Number Publication Date
MX2017008187A true MX2017008187A (es) 2017-09-13

Family

ID=56127737

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008187A MX2017008187A (es) 2014-12-19 2015-12-18 Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2017008173A MX2017008173A (es) 2014-12-19 2015-12-18 Terapias de combinacion con cepas de listeria recombinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017008173A MX2017008173A (es) 2014-12-19 2015-12-18 Terapias de combinacion con cepas de listeria recombinantes.

Country Status (14)

Country Link
US (2) US20180153974A1 (es)
EP (2) EP3234148A4 (es)
JP (2) JP2018501243A (es)
KR (2) KR20170092626A (es)
CN (2) CN107206060A (es)
AU (2) AU2015364255A1 (es)
CA (2) CA2971220A1 (es)
HK (2) HK1246341A1 (es)
IL (2) IL252680A0 (es)
MA (2) MA41218A (es)
MX (2) MX2017008187A (es)
SG (2) SG11201704599PA (es)
TW (2) TW201639594A (es)
WO (2) WO2016100929A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP3332804A1 (en) 2011-03-11 2018-06-13 Advaxis, Inc. Listeria-based adjuvants
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
RU2723050C2 (ru) 2013-05-02 2020-06-08 Анаптисбайо, Инк. Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
JP2017511796A (ja) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド 多標的免疫療法を目的とするバイオマーカー
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
WO2016183361A1 (en) * 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
KR20190101364A (ko) 2016-11-01 2019-08-30 테사로, 인코포레이티드 예정 사멸-1(pd-1)에 대한 항체
WO2018085854A1 (en) * 2016-11-07 2018-05-11 Advaxis, Inc. Combination of listeria-based vaccine with anti-ctla-4 or anti-cd137 antibodies
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN109136275B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
ES3014406T3 (en) 2017-09-19 2025-04-22 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
SG11202008820WA (en) * 2018-03-09 2020-10-29 Advaxis Inc Compositions and methods for evaluating attenuation and infectivity of listeria strains
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
CN110579608B (zh) * 2018-06-11 2022-07-08 苏州若泰医药科技有限公司 一种筛选高表达外源蛋白的非整合减毒李斯特菌菌株的方法
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CN114502587A (zh) * 2019-07-30 2022-05-13 普瑞文森生物有限公司 通过非耗竭性b细胞抑制剂降低免疫原性的方法和组合物
CN114729047A (zh) * 2019-11-21 2022-07-08 百济神州(北京)生物科技有限公司 使用抗ox40抗体与化学治疗剂组合治疗癌症的方法
KR20230038486A (ko) 2020-06-23 2023-03-20 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 호흡기 병원체를 진단하는 방법 및 covid-19 관련 결과를 예측하는 방법
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
US20250188152A1 (en) 2022-03-09 2025-06-12 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
CN114736295B (zh) * 2022-06-14 2022-08-09 北京科跃中楷生物技术有限公司 一种辣根过氧化物酶标记抗体及其制备方法
WO2024258913A1 (en) * 2023-06-16 2024-12-19 Wisconsin Alumni Research Foundation Treatment of solid tumors with a regimen of targeted radionuclide therapy and genetically engineered immune cell therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151942A0 (en) * 2000-03-29 2003-04-10 Univ Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
US10106619B2 (en) * 2006-10-04 2018-10-23 La Jolla Institute For Allergy And Immunology Virus vaccination and treatment methods with OX40 agonist compositions
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CN101214372A (zh) * 2008-01-04 2008-07-09 中国人民解放军第四军医大学 一种体内诱导出针对TNF-α分子的自身抗体的蛋白疫苗的构建方法
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US20140356930A1 (en) * 2013-06-03 2014-12-04 Panacea Pharmaceuticals Immune system enhancing immunotherapy for the treatment of cancer

Also Published As

Publication number Publication date
TW201636360A (zh) 2016-10-16
IL252680A0 (en) 2017-08-31
US20170368157A1 (en) 2017-12-28
HK1246341A1 (zh) 2018-09-07
EP3234148A1 (en) 2017-10-25
HK1245331A1 (zh) 2018-08-24
CN107206060A (zh) 2017-09-26
MA41218A (fr) 2017-10-24
WO2016100924A1 (en) 2016-06-23
MX2017008173A (es) 2017-09-18
KR20170096012A (ko) 2017-08-23
EP3234148A4 (en) 2018-10-17
EP3234106A4 (en) 2018-07-18
US20180153974A1 (en) 2018-06-07
AU2015364260A1 (en) 2017-07-20
MA41217A (fr) 2017-10-24
JP2018501244A (ja) 2018-01-18
CA2971220A1 (en) 2016-06-23
WO2016100929A1 (en) 2016-06-23
AU2015364255A1 (en) 2017-07-20
CA2971455A1 (en) 2016-06-23
SG11201704662SA (en) 2017-07-28
KR20170092626A (ko) 2017-08-11
JP2018501243A (ja) 2018-01-18
EP3234106A1 (en) 2017-10-25
IL252743A0 (en) 2017-08-31
TW201639594A (zh) 2016-11-16
CN107427565A (zh) 2017-12-01
SG11201704599PA (en) 2017-07-28

Similar Documents

Publication Publication Date Title
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
WO2015134722A3 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
MA39849A (fr) Souches de listeria utilisées comme vaccin recombinant et procédé de production
MX2017000836A (es) Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2019005685A (es) Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
MX2019003886A (es) Receptores de antigenos quimericos para el tratamiento del cancer.
MX2019005426A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
PH12017500727A1 (en) Modified virus-like particles of cmv
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
AR110730A1 (es) Vacunas de cepas recombinantes de listeria y método para usarlas en inmunoterapia de cáncer
PH12017500419B1 (en) Recoded arbovirus and vaccines
MX2019007924A (es) Vacunas contra la influenza.
IN2014DN09445A (es)
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
IN2014CN00547A (es)
MX2017016438A (es) Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit.
HK1232448A1 (en) Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
WO2018096399A8 (en) Viral vector constructs for expression of genetic adjuvants activating the cd40 and sting pathways
PH12018500372A1 (en) Fcv recombinant vaccines and uses thereof